/Press Releases

Forge Therapeutics to present at the 18th Annual Needham & Company Healthcare Conference

-Presentation will focus on Forge’s novel chemistry platform, BLACKSMITH, and its therapeutic applications- San Diego, California, March 12, 2019 – Forge Therapeutics, Inc. [...]

2019-03-11T11:07:30-07:00March 11th, 2019|

Forge Receives Second CARB-X Award For Up To $11.1M To Accelerate Development Of Novel Antibiotic To Treat Lung Infections

  San Diego, California, January 3, 2019 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, announced today that [...]

2019-01-03T10:51:05-07:00January 3rd, 2019|

Forge achieves carb-x milestone to advance its lpxc antibiotic to treat infections caused by the world’s deadliest ‘superbugs’

-Technical milestone achievement and program advancement from initial round of ‘Powered by CARB-X’ products- San Diego, California, August 1, 2018 – Forge Therapeutics, [...]

2018-07-31T23:33:37-07:00August 1st, 2018|

Forge announces oral presentation on development of novel antibiotics at the 28th annual ECCMID meeting

San Diego, California, April 9, 2018 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, today announced that David [...]

2018-04-09T06:55:22-07:00April 9th, 2018|

Forge Therapeutics to Present at the 2018 Needham & Company Healthcare Conference

-Presentation will focus on Forge’s portfolio of four novel classes of antibiotics to treat deadly ‘superbug’ infections from Gram-negative bacteria- San Diego, California, [...]

2018-03-21T09:31:14-07:00March 21st, 2018|

Forge Co-founder Presents New Approaches to Treat Infections at the 255th American Chemical Society National Meeting

San Diego, California, March 19, 2018 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, today announced that Professor [...]

2018-03-16T11:24:49-07:00March 19th, 2018|

Forge Therapeutics and collaborators from Evotec and USC present new efficacy data at 2017 Keystone Symposia Conference

-Data demonstrates broad applicability for LpxC inhibitor in Acinetobacter baumannii, a life-threatening respiratory bacteria- LpxC antibiotic is Forge’s flagship program stemming from BLACKSMITH [...]

2017-10-31T01:12:48-07:00October 31st, 2017|

Forge therapeutics announces participation in upcoming scientific and industry events

San Diego, California, October 24, 2017 – Forge Therapeutics, Inc. (Forge) announced today that the company will be participating in several scientific and [...]

2017-10-24T00:35:50-07:00October 23rd, 2017|
Load More Posts